Refeyn has its origins in the University of Oxford Chemistry Department and was founded to commercialise a new technology application in molecular mass measurement. Refeyn is developing a new generation of scientific instrumentation, which uses single molecule light scattering for the detection, imaging and accurate mass determination of biomolecules in solution. Its ‘mass photometry’ instrumentation offers the potential to transform the rapidly emerging biopharma sector and greatly improve the development and production of new biologic drugs.
The technology is designed specifically to be easy to use whilst maintaining the same level of accuracy as much more expensive technologies. As a result, protein research projects will be massively accelerated. The associated increase in productivity translates directly into cost savings and should lead to an acceleration in drug development.
Refeyn will benefit from the investment management and growth experience of Foresight’s team of investment professionals and the product design and manufacturing expertise of WAE.
Cambridge GaN Devices has been created to explore and develop a number of unique opportunities in power electronics.
Flood forecasting and warning mapping systems enable users to protect assets and minimise damage.
Kognitiv Spark develops software to support field service workers in remote locations through 3D augmented & mixed reality holographic displays.
